SSAT - Indirect Costs of Mortality and Morbidity and Direct Economic Costs in a Randomized Controlled Trial of Emergency Therapy of Bleeding Esophageal Varices in Cirrhosis

Indirect Costs of Mortality and Morbidity and Direct Economic Costs in a Randomized Controlled Trial of Emergency Therapy of Bleeding Esophageal Varices in Cirrhosis
Marshall J. Orloff^*¹, Jon I. Isenberg¹, Florin Vaida², Henry O. Wheeler¹, Kevin Haynes¹, Horacio Jinich-Brook¹, Roderick C. Rapier¹, Robert J. Hye¹, Wendy Max³
¹Surgery, University of California, San Diego, San Diego, CA; ²Family and Preventive Medicine/Biostatistics and Bioinformatics, University of California, San Diego, San Diego, CA; ³Institute for Health and Aging, University of California, San Francisco, San Francisco, CA

OBJECTIVE(S): Economic cost is an important measure of effectiveness of treatment of cirrhosis and bleeding esophageal varices (BEV). There have been no reports of costs of any form of emergency treatment of BEV. We examined costs of care in a randomized controlled trial (RCT) that compared endoscopic sclerotherapy (EST) (n=106) to emergency portacaval shunt (EPCS) (n=105), in unselected, consecutive patients (“all comers”).

Back to Annual Meeting Program